Literature DB >> 29293474

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.

Joan D Beckman1, Marian A Rollins-Raval2, Jay S Raval2, Yara A Park2, Marshall Mazepa2, Alice Ma1.   

Abstract

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29293474      PMCID： PMC5753577          DOI： 10.1097/MJT.0000000000000517

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


  5 in total

1.  Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.

Authors:  Marshall A Mazepa; Jay S Raval; Stephan Moll; Alice Ma; Yara A Park
Journal:  Br J Haematol       Date:  2013-12-17       Impact factor: 6.998

2.  Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.

Authors:  Sean Yates; Karen Matevosyan; Cynthia Rutherford; Yu-Min Shen; Ravi Sarode
Journal:  Transfusion       Date:  2014-03-24       Impact factor: 3.157

3.  ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.

Authors:  Jake Shortt; Danielle H Oh; Stephen S Opat
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

Review 4.  Current management of immune thrombocytopenia.

Authors:  Cindy E Neunert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

5.  Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.

Authors:  Nick Willcox; Pilar Martinez-Martinez; Mario Losen; Alejandro M Gomez; Kathleen Vrolix; Jonas Hummel; Gisela Nogales-Gadea; Abhishek Saxena; Hans Duimel; Fons Verheyen; Peter C Molenaar; Wim A Buurman; Marc H De Baets
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422
  5 in total
  6 in total

Review 1.  Immunotherapy for Refractory Autoimmune Encephalitis.

Authors:  Jiawei Yang; Xueyan Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 2.  Recent advances in treatments of adult immune thrombocytopenia.

Authors:  Dae Sik Kim
Journal:  Blood Res       Date:  2022-04-30

Review 3.  Novel Therapies to Address Unmet Needs in ITP.

Authors:  María Eva Mingot-Castellano; José María Bastida; Gonzalo Caballero-Navarro; Laura Entrena Ureña; Tomás José González-López; José Ramón González-Porras; Nora Butta; Mariana Canaro; Reyes Jiménez-Bárcenas; María Del Carmen Gómez Del Castillo Solano; Blanca Sánchez-González; Cristina Pascual-Izquierdo
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-23

Review 4.  Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?

Authors:  Yue Lv; Huiping Shi; Hong Liu; Lu Zhou
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

Review 5.  Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.

Authors:  Sylvain Audia; Matthieu Mahévas; Martin Nivet; Sethi Ouandji; Marion Ciudad; Bernard Bonnotte
Journal:  Hemasphere       Date:  2021-06-01

Review 6.  Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice.

Authors:  Fei Song; Hanny Al-Samkari
Journal:  J Blood Med       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.